Suri Anish 4
4 · Cue Biopharma, Inc. · Filed Apr 4, 2022
Insider Transaction Report
Form 4
Suri Anish
Chief Scientific Officer
Transactions
- Tax Payment
Common Stock
2022-03-31$4.88/sh−7,068$34,492→ 103,638 total - Exercise/Conversion
Restricted Stock Units
2022-03-31−16,668→ 0 total→ Common Stock (16,668 underlying) - Exercise/Conversion
Common Stock
2022-03-31+16,668→ 110,706 total
Footnotes (3)
- [F1]Represents shares of common stock received upon vesting of a restricted stock unit award
- [F2]Each restricted stock unit award represents a contingent right to receive one share of common stock.
- [F3]The restricted stock units vest in three equal annual installments beginning on March 31, 2020.